Stock Events

Stock Events

Editas Medicine 

€2.46
273
-€0.05-1.83% Thursday 06:03

Statistics

Day High
2.46
Day Low
2.46
52W High
3.62
52W Low
1.26
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5AugExpected
Q4 2025
Q1 2026
Next
-0.23
-0.17
-0.11
-0.05
Expected EPS
-0.22899781920999998
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 8EM.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
CRISPR Therapeutics is directly competing in the CRISPR/Cas9 gene-editing space, focusing on developing transformative gene-based medicines for serious diseases.
Intellia Therapeutics
NTLA
Mkt Cap1.58B
Intellia Therapeutics is a leading competitor in the development of in vivo gene editing treatments using CRISPR/Cas9 technology, similar to Editas' approach.
Beam Therapeutics
BEAM
Mkt Cap3.15B
Beam Therapeutics uses base editing, a newer form of gene editing technology that competes with CRISPR/Cas9 methods employed by Editas for precise and reduced-risk gene editing.
Sangamo Therapeutics
SGMO
Mkt Cap55.93M
Sangamo Therapeutics competes with Editas in the broader gene editing market, focusing on zinc finger nuclease (ZFN) technology, an alternative to CRISPR/Cas9.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.51B
Alnylam Pharmaceuticals competes in the RNAi therapeutic space, offering a different approach to gene therapy that could rival Editas' gene editing technologies.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals collaborates with CRISPR Therapeutics on gene editing therapies, indirectly competing with Editas through their joint development efforts in the CRISPR/Cas9 space.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other genetic disorder treatments, competing with Editas in the broader market for genetic disease therapies.
PTC Therapeutics
PTCT
Mkt Cap5.43B
PTC Therapeutics operates in the genetic disorder space, offering treatments that could compete with gene editing therapies developed by Editas.
Ionis Pharmaceuticals
IONS
Mkt Cap12.44B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, presenting a competitive alternative to Editas' gene editing approach.

About

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Show more...
CEO
Dr. Gilmore O'Neill M.D.
Employees
87
Country
United States
ISIN
US28106W1036

Listings

LSE
GB
0IFK.LSE
MU
DE
8EM.MU
STU
DE
8EM.STU
XNAS
US
EDIT

0 Comments

Share your thoughts

FAQ

What is Editas Medicine stock price today?▼
The current price of 8EM.MU is €2.46 EUR — it has decreased by -1.83% in the past 24 hours. Watch Editas Medicine stock price performance more closely on the chart.
What is Editas Medicine stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Editas Medicine stocks are traded under the ticker 8EM.MU.
Is Editas Medicine stock price growing?▼
8EM.MU stock has fallen by -1.83% compared to the previous week, the month change is a +13.39% rise, over the last year Editas Medicine has showed a +76.63% increase.
When is the next Editas Medicine earnings date?▼
Editas Medicine is going to release the next earnings report on August 05, 2026.
What were Editas Medicine earnings last quarter?▼
8EM.MU earnings for the last quarter are -0.22 EUR per share, whereas the estimation was -0.22 EUR resulting in a +1.15% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Editas Medicine have?▼
As of May 06, 2026, the company has 87 employees.
In which sector is Editas Medicine located?▼
Editas Medicine operates in the Other sector.
When did Editas Medicine complete a stock split?▼
Editas Medicine has not had any recent stock splits.
Where is Editas Medicine headquartered?▼
Editas Medicine is headquartered in Cambridge, United States.